These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 29800950)

  • 1. Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series.
    Frezza AM; Jones RL; Lo Vullo S; Asano N; Lucibello F; Ben-Ami E; Ratan R; Teterycz P; Boye K; Brahmi M; Palmerini E; Fedenko A; Vincenzi B; Brunello A; Desar IME; Benjamin RS; Blay JY; Broto JM; Casali PG; Gelderblom H; Grignani G; Gronchi A; Hall KS; Mir O; Rutkowski P; Wagner AJ; Anurova O; Collini P; Dei Tos AP; Flucke U; Hornick JL; Lobmaier I; Philippe T; Picci P; Ranchere D; Renne SL; Sbaraglia M; Thway K; Wagrodzki M; Wang WL; Yoshida A; Mariani L; Kawai A; Stacchiotti S
    JAMA Oncol; 2018 Sep; 4(9):e180219. PubMed ID: 29800950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network.
    Frezza AM; Assi T; Lo Vullo S; Ben-Ami E; Dufresne A; Yonemori K; Noguchi E; Siontis B; Ferraro R; Teterycz P; Duffaud F; Ravi V; Vincenzi B; Gelderblom H; Pantaleo MA; Baldi GG; Desar I; Fedenko A; Maki RG; Jones RL; Benjamin RS; Blay JY; Kawai A; Gounder M; Gronchi A; Le Cesne A; Mir O; Czarnecka AM; Schuetze S; Wagner AJ; Adam J; Barisella M; Sbaraglia M; Hornick JL; Meurgey A; Mariani L; Casali PG; Thornton K; Stacchiotti S
    Cancer; 2020 Jan; 126(1):98-104. PubMed ID: 31536651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma.
    Gounder MM; Merriam P; Ratan R; Patel SR; Chugh R; Villalobos VM; Thornton M; Van Tine BA; Abdelhamid AH; Whalen J; Yang J; Rajarethinam A; Duh MS; Bobbili PJ; Huynh L; Totev TI; Lax AK; Agarwal S; Demetri GD
    Cancer; 2021 Apr; 127(8):1311-1317. PubMed ID: 33296083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas).
    Sanfilippo R; Jones RL; Blay JY; Le Cesne A; Provenzano S; Antoniou G; Mir O; Fucà G; Fumagalli E; Bertulli R; Stacchiotti S; Brahmi M; Grosso F; Dufresne A; Hindi N; Sbaraglia M; Gronchi A; Collini P; Dei Tos AP; Casali PG
    Clin Cancer Res; 2019 Sep; 25(17):5295-5300. PubMed ID: 31217199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial.
    Schmoll HJ; Lindner LH; Reichardt P; Heißner K; Kopp HG; Kessler T; Mayer-Steinacker R; Rüssel J; Egerer G; Crysandt M; Kasper B; Niederwieser D; Kunitz A; Eigendorff E; Petersen I; Steighardt J; Cygon F; Meinert F; Stein A
    JAMA Oncol; 2021 Feb; 7(2):255-262. PubMed ID: 33355646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma.
    Stacchiotti S; Mir O; Le Cesne A; Vincenzi B; Fedenko A; Maki RG; Somaiah N; Patel S; Brahmi M; Blay JY; Boye K; Sundby Hall K; Gelderblom H; Hindi N; Martin-Broto J; Kosela H; Rutkowski P; Italiano A; Duffaud F; Kobayashi E; Casali PG; Provenzano S; Kawai A
    Oncologist; 2018 Jan; 23(1):62-70. PubMed ID: 28754721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma.
    Somaiah N; Van Tine BA; Wahlquist AE; Milhem MM; Hill EG; Garrett-Mayer E; Armeson KE; Schuetze SM; Meyer CF; Reuben DY; Elias AD; Read WL; Chawla SP; Kraft AS
    Cancer; 2021 Mar; 127(6):894-904. PubMed ID: 33231866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature.
    Frezza AM; Ravi V; Lo Vullo S; Vincenzi B; Tolomeo F; Chen TW; Teterycz P; Baldi GG; Italiano A; Penel N; Brunello A; Duffaud F; Hindi N; Iwata S; Smrke A; Fedenko A; Gelderblom H; Van Der Graaf W; Vozy A; Connolly E; Grassi M; Benjamin RS; Broto JM; Grignani G; Jones RL; Kawai A; Tysarowski A; Mariani L; Casali PG; Stacchiotti S
    Cancer Med; 2021 Apr; 10(8):2645-2659. PubMed ID: 33713582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-grade fibromyxoid sarcoma and sclerosing epithelioid fibrosarcoma, outcome of advanced disease: retrospective study from the Ultra-Rare Sarcoma Working Group.
    Giani C; Denu RA; Ljevar S; Gronchi A; Napolitano A; Rosenbaum E; Salawu A; Bajpai J; Connolly EA; Lee ATJ; Trent JC; Koseła-Paterczyk H; Chia-Chen Li Z; Ogura K; Palmerini E; Baldi GG; Brunello A; Campos F; Cicala CM; Maki RG; Wagner AJ; Andelkovic V; Loong HH; Wong DD; Jones RL; Tap WD; Taverna SM; Lazar AJ; Demicco EG; Hong A; Bovee JVMG; Dei Tos AP; Fletcher CDM; Baumhoer D; Sbaraglia M; Schaefer IM; Miceli R; Stacchiotti S
    ESMO Open; 2024 Sep; 9(9):103689. PubMed ID: 39265219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis.
    Baldi GG; Brahmi M; Lo Vullo S; Cojocaru E; Mir O; Casanova M; Vincenzi B; De Pas TM; Grignani G; Pantaleo MA; Blay JY; Jones RL; Le Cesne A; Frezza AM; Gronchi A; Collini P; Dei Tos AP; Morosi C; Mariani L; Casali PG; Stacchiotti S
    Oncologist; 2020 Nov; 25(11):e1777-e1784. PubMed ID: 32584482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine and docetaxel for epithelioid sarcoma: results from a retrospective, multi-institutional analysis.
    Pink D; Richter S; Gerdes S; Andreou D; Tunn PU; Busemann C; Ehninger G; Reichardt P; Schuler MK
    Oncology; 2014; 87(2):95-103. PubMed ID: 25011671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma.
    Kim JH; Park HS; Heo SJ; Kim SK; Han JW; Shin KH; Kim SH; Hur H; Kim KS; Choi YD; Kim S; Lee YH; Suh JS; Ahn JB; Chung HC; Noh SH; Rha SY; Kim HS
    Oncology; 2019; 96(2):59-69. PubMed ID: 30336470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas.
    Munhoz RR; D'Angelo SP; Gounder MM; Keohan ML; Chi P; Carvajal RD; Singer S; Crago AM; Landa J; Healey JH; Qin LX; Hameed M; Ezeoke MO; Singh AS; Agulnik M; Chmielowski B; Luke JJ; Van Tine BA; Schwartz GK; Tap WD; Dickson MA
    Oncologist; 2015 Nov; 20(11):1245-6. PubMed ID: 26449382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial.
    Karch A; Koch A; Grünwald V
    Trials; 2016 Jul; 17(1):312. PubMed ID: 27387325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study).
    Pautier P; Penel N; Ray-Coquard I; Italiano A; Bompas E; Delcambre C; Bay JO; Bertucci F; Delaye J; Chevreau C; Cupissol D; Bozec L; Eymard JC; Saada E; Isambert N; Guillemet C; Rios M; Piperno-Neumann S; Chenuc G; Duffaud F
    Eur J Cancer; 2020 Jan; 125():31-37. PubMed ID: 31835236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of pazopanib in patients with metastatic or unresectable chemoresistant sarcomas: A Japanese Musculoskeletal Oncology Group study.
    Urakawa H; Kawai A; Goto T; Hiraga H; Ozaki T; Tsuchiya H; Nakayama R; Naka N; Matsumoto Y; Kobayashi E; Okuma T; Kunisada T; Ando M; Ueda T; Nishida Y
    Cancer Sci; 2020 Sep; 111(9):3303-3312. PubMed ID: 32579783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
    Richardson DL; Sill MW; Coleman RL; Sood AK; Pearl ML; Kehoe SM; Carney ME; Hanjani P; Van Le L; Zhou XC; Alvarez Secord A; Gray HJ; Landrum LM; Lankes HA; Hu W; Aghajanian C
    JAMA Oncol; 2018 Feb; 4(2):196-202. PubMed ID: 29242937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial.
    Jones RL; Ravi V; Brohl AS; Chawla S; Ganjoo KN; Italiano A; Attia S; Burgess MA; Thornton K; Cranmer LD; Cheang MCU; Liu L; Robertson L; Adams B; Theuer C; Maki RG
    JAMA Oncol; 2022 May; 8(5):740-747. PubMed ID: 35357396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How we use pazopanib in treating soft-tissue sarcoma: experience at our multidisciplinary sarcoma centers.
    Van Tine BA; Trent JC
    Curr Med Res Opin; 2019 Apr; 35(4):623-629. PubMed ID: 30652922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors.
    Plummer R; Madi A; Jeffels M; Richly H; Nokay B; Rubin S; Ball HA; Weller S; Botbyl J; Gibson DM; Scheulen ME
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):93-101. PubMed ID: 23064954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.